# Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

> **NCT02088684** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 70 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** LEE011
- **DRUG:** BYL719
- **DRUG:** fulvestrant
- **DRUG:** BKM120

## Key facts

- **NCT ID:** NCT02088684
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-19
- **Primary completion:** 2018-04-17
- **Final completion:** 2018-04-17
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02088684

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02088684, "Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02088684. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*